Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CTNM

Contineum Therapeutics Inc.

Sep 27 • 04:00PM ET

18.84

Dollar change +0.17
Percentage change 0.91	%

Healthcare • Biotechnology • USA • NASD

Held by: VTI IWM VXF VTWO IWO SCHA IWN IWC GSSC VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-	Insider Own	44.95%	Shs Outstand	23.40M	Perf Week	-5.04%
Market Cap	484.56M	Forward P/E	-	EPS next Y	-1.65	Insider Trans	0.00%	Shs Float	14.16M	Perf Month	1.95%
Income	-	PEG	-	EPS next Q	-0.40	Inst Own	37.09%	Short Float	5.75%	Perf Quarter	6.98%
Sales	-	P/S	-	EPS this Y	-4322.22%	Inst Trans	-	Short Ratio	11.14	Perf Half Y	-
Book/sh	8.46	P/B	2.23	EPS next Y	13.42%	ROA	-	Short Interest	0.81M	Perf Year	-
Cash/sh	8.50	P/C	2.22	EPS next 5Y	-	ROE	-	52W Range	13.27 - 22.00	Perf YTD	22.34%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-14.36%	Beta	-
Dividend TTM	-	Quick Ratio	58.92	Sales past 5Y	0.00%	Gross Margin	-	52W Low	41.97%	ATR (14)	1.26
Dividend Ex-Date	-	Current Ratio	58.92	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	51.30	Volatility	6.01% 7.02%
Employees	31	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	28.67
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-86.77%	Payout	-	Rel Volume	0.26	Prev Close	18.67
Sales Surprise	-	EPS Surprise	-12.23%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	73.05K	Price	18.84
SMA20	2.22%	SMA50	0.30%	SMA200	6.56%	Trades		Volume	19,281	Change	0.91%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	Stifel	Buy	$29
Apr-30-24	Initiated	RBC Capital Mkts	Outperform	$30
Apr-30-24	Initiated	Morgan Stanley	Overweight	$25

Aug-28-24 04:05PM	Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences (Business Wire) -7.00%
Aug-13-24 04:05PM	Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire) -6.06% +6.21%
Jul-31-24 04:05PM	Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis (Business Wire) -5.33%
Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-04-24 04:05PM	Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference (Business Wire)
04:05PM	Loading…
Jun-03-24 04:05PM	Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary (Business Wire)
May-20-24 04:05PM	Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors (Business Wire)
May-16-24 04:05PM	Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Apr-04-24 09:02PM	Contineum Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Huhn Stephen L.	CMO & Sr VP, Clinical Dev.	Aug 13 '24	Option Exercise	1.01	12,800	12,928	12,800	Aug 14 06:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTNM

Contineum Therapeutics Inc.

Upgrade your FINVIZ experience